Company profile

Luminary Therapeutics, Inc.

Privately held: no public share price (Luminary Therapeutics (Minneapolis, MN) is a privately held clinical-stage allogeneic cell-therapy company (LMY-920 BAFF-CAR-T for multiple myeloma), backed by the Myeloma Investment Fund among others (themmrf.org, luminarytx.com). No public listing found. Sources: https://clinicaltrials.gov/study/NCT05546723 Entity resolved by asset-pipeline-v2.)

Assets

(2 total)

2Total Assets

0Approved

0Phase 3 / Filed

2Phase 1–2 / Early

1Diseases

Showing 2 of 2 assets

		Target & Modality
LMY-920	Phase 1	BCMA / TACICell therapy	Multiple Myeloma
LMY-922	Phase 1	BCMA, BAFF-R (TNFRSF13C), TACI (TNFRSF13B)Cell therapy	Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.